EXPLORING THE ANTIDIABETIC, LIPID-LOWERING, AND TISSUE REPAIR BENEFITS OF MULTI-COMPONENT MICROSPHERES IN STREPTOZOTOCIN-INDUCED DIABETIC RATS
DOI:
https://doi.org/10.22159/ajpcr.2025v18i5.54330Keywords:
Dapagliflozin, Linagliptin, Metformin, Microspheres,, Type II diabetes, Lipid profileAbstract
Objective: Dapagliflozin, linagliptin, and metformin are extensively utilized either alone or in combination to manage insulin-resistant diabetes. However, the precise administration and effectiveness of their triple combination through a microsphere formulation is yet to be thoroughly explored. This study sets out to explore the antidiabetic and hypolipidemic effects, as well as the histopathological impact of microspheres drug delivery system in streptozotocin (STZ)-administered diabetic rats.
Methods: Following an overnight fast, both healthy and diabetic rats were separated into five sets each containing six rats, receiving daily oral treatments for 21 days. Group 1 (control) was administered saline (0.9% NaCl), Group 2 (STZ) received STZ (65 mg/kg through an intraperitoneal injection.), Group 3 (STZ and metformin) received metformin (150 mg/kg), Group 4 (STZ and empagliflozin + linagliptin + metformin) received a tablet combination of these drugs, and Group 5 (STZ and dapagliflozin+linagliptin+metformin) was treated with dapagliflozin (5 mg/kg), linagliptin (5 mg/kg), and metformin microspheres (150 mg/kg). Plasma glucose concentration was monitored weekly, and lipid functions were assessed after 21 days. Histopathological examinations of the pancreas and kidneys were also conducted.
Results: The microsphere combination of dapagliflozin, linagliptin, and metformin significantly improved blood glucose levels (109.10±4.13 mg/dL), renal and hepatic functions, and showed beneficial effects on lipid parameters, particularly high-density lipoprotein levels (32.17±3.4 mg/dL), which could lower risk of cardiovascular diseases. Histopathological analysis revealed positive effects on the pancreas and kidneys. A p<0.05 was considered to indicate statistical significance.
Conclusion: The microsphere formulation of the triple drug combination demonstrates synergistic antidiabetic properties, enhances body weight, improves lipid profiles, and supports renal and hepatic functions. In addition, it protects against tissue damage to the pancreas and kidneys in STZ-mediated experimental diabetes.
Downloads
References
Venkataraman S, Manasa M. Pharmaceutical analysis and diabetes mellitus - A review. Asian J Pharm Clin Res. 2018;11(4):23-8. doi: 10.22159/ajpcr.2018.v11s4.31702
Banday MZ, Sameer AS, Nissar S. Pathophysiology of diabetes: An overview. Avicenna J Med. 2020;10(4):174-88. doi: 10.4103/ajm. ajm_53_20, PMID 33437689
Sharma S, Kashyap A, Biswal PK, Das SN. Recent approaches in glucose responsive insulin delivery systems. Asian J Pharm Clin Res. 2022;15(2):18-29. doi: 10.22159/ajpcr.2022.v15i2.43572
Lou J, Duan H, Qin Q, Teng Z, Gan F, Zhou X, et al. Advances in oral drug delivery systems: Challenges and opportunities. Pharmaceutics. 2023;15(2):484. doi: 10.3390/pharmaceutics15020484, PMID 36839807
Adepu S, Ramakrishna S. Controlled drug delivery systems: Current status and future directions. Molecules. 2021;26(19):5905. doi: 10.3390/ molecules26195905, PMID 34641447
Kakkar V, Wani SU, Gautam SP, Qadrie ZL. Role of microspheres in novel drug delivery systems: Preparation methods and applications. Int J Curr Pharm Res. 2020;12(3):10-5. doi: 10.22159/ijcpr.2020v12i3.38326
Cheng M, Ren L, Jia X, Wang J, Cong B. Understanding the action mechanisms of metformin in the gastrointestinal tract. Front Pharmacol. 2024;15:1347047. doi: 10.3389/fphar.2024.1347047, PMID 38617792
Sarkar S, Sadhu S, Roy R, Tarafdar S, Mukherjee N, Sil M, et al. Contemporary drifts in diabetes management. Int J Appl Pharm. 2023;15(2):1-9. doi: 10.22159/ijap.2023v15i2.46792
Fonseca-Correa JI, Correa-Rotter R. Sodium-glucose cotransporter 2 inhibitors mechanisms of action: A review. Front Med (Lausanne). 2021;8:777861. doi: 10.3389/fmed.2021.777861, PMID 34988095
Mishra R, Dhole S. Dipeptidyl peptidase-4 inhibitors: Potential for treatment of metabolic syndrome and developed formulation approaches. Asian J Pharm Clin Res. 2017;10(11):20-6. doi: 10.22159/ ajpcr.2017.v10i11.20342
Pal R, Mujahid M, Ahmad S. Formulation development and in-vitro evaluation of linagliptin transdermal patch using permeability enhancer. Int J Pharm Sci Rev Res. 2023;82(1):19-28. doi: 10.47583/ijpsrr.2023. v82i01.004
Jain A, Vispute A, Dange A, Naskar A, Mondal A, Vivekanand B, et al. A randomized, double-blind, parallel-group phase III trial investigating the glycemic efficacy and safety profile of fixed-dose combination dapagliflozin and linagliptin over linagliptin monotherapy in patients with inadequately controlled type 2 diabetes with metformin. Diabetes Ther. 2023 Nov 14;15(11):215-27. doi: 10.1007/s13300-023-01504-3
Rai SY, Ravikumar P. Development and evaluation of microsphere based topical formulation using design of experiments. Indian J Pharm Sci. 2016;78(2):182-92. doi: 10.4172/pharmaceutical-sciences.1000102
Prasanthi D, Deepika Y, Rama Devi S. Formulation and evaluation of linagliptin mucoadhesive microspheres. Int Res J Pharm. 2018;9(5):11-7. doi: 10.7897/2230-8407.09567
Das MK, Ahmed AB, Saha D. Microsphere a drug delivery system - A review. Int J Curr Pharm Res. 2019;11(4):34-41. doi: 10.22159/ ijcpr.2019v11i4.34941
Abdallah MH. Box-Behnken design for development and optimization of acetazolamide microspheres. Int J Pharm Sci Res. 2014;5(4):1228-39. doi: 10.13040/IJPSR.0975-8232.5(4).1228-39
Pereira S, Veeraraghavan P, Ghosh S, Gandhi M. Animal experimentation and ethics in India: the CPCSEA makes a difference. Altern Lab Anim. 2004 Jun;32 Suppl 1B:411-5. doi: 10.1177/026119290403201s67, PMID 23581110
Furman BL. Streptozotocin-induced diabetic models in mice and rats. Curr Protoc. 2021;1(4):e78. doi: 10.1002/cpz1.78, PMID 33905609
Rehman HU, Ullah K, Rasool A, Manzoor R, Yuan Y, Tareen AM, et al. Comparative impact of streptozotocin on altering normal glucose homeostasis in diabetic rats compared to normoglycemic rats. Sci Rep. 2023;13(1):7921. doi: 10.1038/s41598-023-29445-8, PMID 37193696
Chakra BK, Debnath S, Mukherjee A, Kuotsu K, Chakraborty M, Chatterjee TK. Potent anti-diabetic activity of polymeric microsphere formulated metformin on streptozotocin-induced diabetic rat model. Int J Life Sci Pharm Res. 2022;12(2):68-81. doi: 10.22376/ijpbs/ lpr.2022.12.2
Carlson DB, Bourcier T, Yanoff L, White M. Empagliflozin/ Linagliptin/Metformin XR FDC for the Treatment of Type 2 Diabetes Mellitus. In: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Pharmacology/Toxicology NDA Review and Evaluation. Application Number NDA 212614 [Supporting Document SDN-1]. United States: Boehringer Ingelheim Pharmaceuticals, Inc. Available from: https:// www.fda.gov
Kumar S, Kumar V, Prakash O. Antidiabetic, hypolipidemic and histopathological analysis of Dillenia indica (L.) leaves extract on alloxan induced diabetic rats. Asian Pac J Trop Med. 2011;4(5):347-52. doi: 10.1016/S1995-7645(11)60101-6, PMID 21771674
Min E, Aimakov N, Lee S, Ban S, Yang H, Ahn Y, et al. Multi-contrast digital histopathology of mouse organs using quantitative phase imaging and virtual staining. Biomed Opt Express. 2023;14(5):2068-79. doi: 10.1364/BOE.484516, PMID 37206137
Chakra BK, Karan S, Das B, Debnath S, Chatterjee TK. A controlled release microsphere formulation of an anti-diabetic drug and characterization of the microsphere. Int J Pharm Pharm Sci. 2018;10(10):151-7. doi: 10.22159/ijpps.2018v10i10.27541
Mishra GP, Sharma R, Jain M, Bandyopadhyay D. Syntheses, biological evaluation of some novel substituted benzoic acid derivatives bearing hydrazone as linker. Res Chem Intermed. 2021;47(12):5061-78. doi: 10.1007/s11164-021-04555-y
Published
How to Cite
Issue
Section
Copyright (c) 2025 Dr. Surbhi Gupta, ANUSHREE CHAUHAN , Prabhat Singh, GANESH PRASAD MISHRA
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
